Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors

NCT06956690 is registered in ClinicalTrials.gov with Hummingbird Bioscience as lead sponsor.

NCT NCT06956690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06956690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors
Lead sponsor
Hummingbird Bioscience
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 17, 2025
Completion date
July 31, 2027
Enrollment
180 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, melanoma (skin), non small cell lung cancer